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ABSTRACT (278 words)  
Background:  Attention deficit hyperactivity disorder is increased in children with 
intellectual disability. Previous research has suggested stimulants are less effective than in 
typically developing children but no studies have titrated medication for individual optimal 
dosing or tested the effects for longer than 4 weeks.  
Method:  122 drug-free children aged 7-15 with hyperkinetic disorder and IQ 30-69 were 
recruited to a double blind, placebo-controlled trial that randomized participants using 
minimization by probability, stratified by referral source and IQ level in a one to one ratio. 
Methylphenidate was compared to placebo. Dose titration comprised at least one week each 
of low (0·5 mgs/kg/day), medium (1·0 mgs/kg/day) and high dose (1·5 mgs/kg/day). Parent 
and teacher ADHD index of the Conners Rating Scale-Short Version at 16 weeks provided 
the primary outcome measures. Clinical response was determined with the Clinical Global 
Impressions scale (CGI-I). Adverse effects were evaluated by a parent-rated questionnaire, 
weight, pulse and blood pressure. Analyses were by intention-to treat.  
Results: Methylphenidate was superior to placebo with effect sizes of 0.39 [95% confidence 
intervals (CIs) 0.09, 0.70] and 0.52 (95% CIs 0.23, 0.82) for the parent and teacher Conners 
ADHD index.  Four (7%) children on placebo versus 24 (40%) of those on methylphenidate 
were judged improved or much improved on the CGI. IQ and autistic symptoms did not affect 
treatment efficacy. Active medication was associated with sleep difficulty, loss of appetite 
and weight loss but there were no significant differences in pulse or blood pressure.  
Conclusions: Optimal dosing of methylphenidate is practical and effective in some children 
with hyperkinetic disorder and intellectual disability. Adverse effects typical of 
methylphenidate were seen and medication use may require close monitoring in this 
vulnerable group. 
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Attention deficit hyperactivity disorder (ADHD) and the more severe hyperkinetic 
disorder (HD) are characterized by levels of overactivity, inattention and impulsivity that are 
developmentally inappropriate and pervasive across different situations such as home, school 
and leisure activities.  An association with subaverage intelligence is consistently identified; 
one epidemiological study reported an 8-fold increase in the rate of HD among children with 
global learning problems (Emerson, 2003) and another reported a 16-point decrease in IQ of 
those meeting a questionnaire algorithm for HD (Simonoff, Pickles, Wood, Gringras, and 
Chadwick, 2007). The latter study demonstrated that the psychiatric and cognitive correlates 
of HD were similar in those with IQ 40-69 compared to those of normal ability and showed 
both groups experienced similar psychosocial impact of HD. 
Guidelines on medical management recommend methylphenidate as the first line 
(Pliszka, et al., 2006; Taylor, et al., 2004). The MTA trial demonstrated that  individually 
titrated medication was significantly better than either treatment as usual (mostly medication), 
suggesting that individual dose selection is important in optimizing behavioural improvement 
(MTA Cooperative Group, 1999).  
Most treatment trials for ADHD have excluded children with intellectual disability 
(ID) and the evidence pertaining to this group is restricted to a handful of studies.  (Aman, 
Buican, and Arnold, 2003) aggregated the studies from his group, concluding that there was 
consistent evidence for a moderate effect size (0.57 for teachers, 0.39 for parents) but that this 
was considerably less than reported in studies with typically developing children, e.g.,~0.8-
0.9 in the MTA titration trial (Greenhill, et al., 2001).  Other groups (Handen, Feldman, 
Lurier, and Murray, 1999; Pearson, et al., 2003) consistently find similar moderate effects of 
methylphenidate. Aman’s aggregated analysis further suggested that lower IQ/mental age 
predicted a poorer medication response. However, design limitations in all these studies affect 
the interpretation and resulting confidence in the evidence base.  First, all recent studies were 
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crossover in design; the success of blinding was not consistently reported and there is often 
low power to detect order effects. Second, all trials were short-term in duration (2-4 weeks 
follow-up) and do not assess the medium- to long-term efficacy of ADHD treatment.  Third, 
dosing regimens in some older trials did not follow current practice; all used immediate 
release formulation in twice rather than three times daily dosing and none used individual 
dose titration. Finally, sample sizes were very small (11-35 participants), producing imprecise 
estimates and not allowing tests of moderator effects. The latter are particularly important as 
both clinical reports (Campbell, 1978) and theoretical grounds (Barkley, McMurray, 
Edelbrock, and Robbins, 1992) suggest that those with autism may be particularly sensitive to 
adverse effects s and prone to develop more tics, rituals/compulsions, stereotyped behaviours, 
irritability and social withdrawal (Handen, Johnson, and Lubetsky, 2000; Quintana, et al., 
1995). A recent larger randomized controlled crossover trial in children with autism spectrum 
disorders (ASDs) and high levels of hyperactivity (Research Units on Pediatric 
Psychopharmacology (Autism Network), 2005) reported beneficial effects of stimulants 
amongst those tolerating medication but 13 of 72 (18%) withdrew due to adverse effects. 
The present trial of immediate-release methylphenidate versus placebo in children 
with ID and hyperkinetic disorder aimed to answer the question, as set out in the protocol: (1) 
What is the efficacy and safety of stimulant medication over 16 weeks, under conditions of 
individual optimal dose titration; (2) What is the profile of adverse effects in this population; 
and (3) Is efficacy moderated by the level of ID, the presence of autistic symptoms or the 
severity of ADHD symptoms? 
 
METHODS 
This was a randomized controlled double-blind trial of immediate-release 
methylphenidate versus placebo individually titrated over 3 or more weeks followed by 
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optimal dose until 16 weeks post-randomization. Participants were allocated to treatments 
through the Mental Health and Neuroscience Clinical Trials Unit (CTU-London, UK). 
Allocation was undertaken independently of the trial team. The first 15 participants were 
allocated with simple randomisation. Thereafter, allocation was stratified by source of referral 
(clinical referral or community screening) and ID (full scale IQ score <50 or ≥50) with 
computer-generated probabilistic minimisation. Once notified by the CTU, the pharmacy 
dispensed the trial medication. An open-label phase (not described) followed the double-blind 
trial in which participants receiving placebo medication were offered active medication and 
those on active medication could continue methylphenidate treatment, including dose and 
formulation alternations.  Ethical and regulatory approval was obtained from the Southeast 
Multi-Centre Research Ethics Committee (MREC +04/01/013) and Medicines and Healthcare 
Products Regulatory Authority (MHRA 8000/13629).  
Participants were recruited through clinical referrals and community screening across 
the south-east of England and all assessments were completed by trial team members based at 
the Institute of Psychiatry. Paediatricians and child psychiatrists in the recruitment areas were 
informed of the trial and all clinical referrals were offered an eligibility assessment. 
Community screening employed two methods.  In four health districts there was an up-to date 
Special Educational Needs Register, a database listing children requiring high levels of 
educational support; and children were identified whose difficulties suggested they might be 
eligible.  Second, individual special schools for children with ID in the recruitment areas were 
individually approached. Screening employed the short form of the Conners Rating Scale 
(Conners, 1989); children were approached for an eligibility assessment if they received a 
Conners score (1) above the age-normed 90
th
  centile on either parent ADHD index or 
hyperactivity scale and (2) above the 85
th
 centile on either the teacher ADHD index or 
hyperactivity scale. 
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Participant inclusion criteria were: 7-15 years of age; a diagnosis of ICD-10 
hyperkinetic disorder; and a full-scale IQ of 30-69.  Diagnosis of hyperkinetic disorder was 
made using the Child and Adolescent Psychiatric Assessment (CAPA; Angold, et al., 1995) 
and details of implementation and IQ assessment are provided in the supplementary appendix. 
Symptoms of autism were measured with the parent-reported Social Communication 
Questionnaire (SCQ; Rutter, Bailey, and Lord, 2003) but the ICD-10 exclusion rule of an 
ASD was not employed. A psychiatric and medical history was undertaken at screening and 
each child received a physical examination.  Further inclusion criteria were: living in a stable 
situation and regular school attendance.  Exclusion criteria were: current stimulant use; use of 
neuroleptic medication in the last six months; history of a sensitivity reaction to stimulant 
medication; a diagnosis of a dementing disorder; epilepsy with daily seizures; presence of a 
psychotic, bipolar, severe obsessive-compulsive disorder or severe Tourette syndrome; or a 
household resident with a current substance abuse disorder.  Only one child per family was 
enrolled in the double-blind phase at any one time. Written informed consent was obtained 
prior to randomization from parents/legal guardians of participants with assent of children as 
appropriate for their level of understanding.   
Medication 
 Immediate-release methylphenidate supplied as Equasym
® 
in 5, 10 and 20 mgs tablets 
comprised the active treatment; a matching placebo in identical ‘doses’ was manufactured by 
the Guy’s and St. Thomas’ Pharmaceutical Production Laboratory, which is approved by the 
UK MHRA.  
Optimal dose titration and selection 
 This procedure aimed to assess participants on three daily doses: 0.5 (low dose). 1.0 
(medium) and 1.5 (high) mgs/kg, given in increasing dose and delivered three times daily. At 
the end of titration, two senior medical investigators (ES, ET, GB and SB) independently 
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judged optimal dose for each participant using parent, teacher and clinician ratings on adverse 
events and behavioural improvement on the parent and teacher Conners ADHD index and 
hyperactivity scale. This dose was then prescribed for the remainder of the 16 week trial. (See 
supplementary appendix for details.) 
Measures of efficacy 
The primary outcome measures for this study were the parent and teacher Conners 
ADHD index at 16 weeks. Secondary outcome measures at 16 weeks included scores on the 
parent and teacher Conners hyperactivity scale and hyperactivity subscale of the Aberrant 
Behavior Checklist (ABC;). The Clinical Global Impressions-Improvement rating (CGI-I; 
Sharkey, 1985) was completed by the clinician with the parent at the 16-week assessment; 
ratings of ‘improved,’ ‘much improved’ and  ‘completely recovered’ were categorized post 
hoc as a clinical response.  
Safety 
 Possible adverse effects were monitored during dose titration and at the 8, 12 and 16 
weeks post randomization visits, as described in the supplementary appendix.  Because the 
optimal dosing design involved the trial of doses that may evoke short-term adverse effects, 
the primary interest was in adverse effects present at 16 weeks, on optimal dose, as measured 
by the parent questionnaire.  Behaviours of a priori interest for individual analysis were: 
parent-rated sleep difficulties, poor appetite, looks sad/miserable, crying spells, looks anxious, 
meaningless repetitive behaviour and social withdrawal (talks less than usual with other 
children), with significant worsening classified as a two-point deterioration from baseline.  In 
addition, two aggregate scores were calculated post hoc. The target adverse effects score 
summed the behaviours listed above and aimed to identify smaller differences across several 
adverse effects. The other adverse effects score comprised the other behaviours of the adverse 
effects questionnaire: stares a lot or daydreams; not interested in other children; irritable; 
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complains of stomach ache; complains of headache; drowsy; seems unsteady; excited; angry; 
has nightmares; displays twitches (tics); and shaking or tremor of hands. Changes in weight, 
pulse and blood pressure were also considered.  We observed children who were withdrawn 
from medication because of adverse effects. 
Statistical analysis 
No formal interim analyses were performed. Sample size calculations were based on 
an effect size of 0·5 in the differential reduction in symptoms between baseline and 16 weeks 
(Research Units on Pediatric Psychopharmacology (Autism Network), 2005) . A sample size 
of 64 per group gives 80% (α=·05, two-tailed) power. The analyses, using Stata version 11, 
followed a pre-specified plan and were performed on the intention-to-treat sample. Effect 
sizes were calculated as the estimated adjusted treatment effect divided by the pooled within 
group standard deviation of the outcome. Linear regression models were fitted for each 
outcome. All models included a fixed contrast for the treatment effect, the randomization 
stratification factors, age, sex, and baseline SCQ score. The screening and baseline values of 
the outcome were included as fixed covariates.   
The moderator effects specified a priori were: severity of ID (baseline full-scale IQ), autistic 
symptoms (baseline SCQ score) and ADHD severity (baseline parent and teacher Conners 
ADHD index). Moderator analyses were performed on both primary outcomes by including 
an interaction between treatment and moderator and the results considered exploratory. 
The adverse events measured on a continuous scale were examined using linear regression 
while binary events were examined using exact logistic regression, with contrasts for 
treatment, source and severity in each case. The two adverse effects scores were examined 
using separate regression analyses with contrasts for treatment, severity, source, gender and 
the covariates age and baseline SCQ. All other safety data are reported descriptively.  
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As a sensitivity analysis, the primary analyses were repeated including only compliers 
who took most or all medication doses as determined by parent and teacher report and 
clinician judgement. All statistical tests are two-sided. 
Missing data were treated as missing at random and imputed using multiple 
imputation (Rubin, 1987) by chained equations (Van Buuren, Boshuizen, and Knook, 1999) 
using the ice package (version 1.1.4 (Royston, 2005)). The results of 200 imputed datasets 
were combined using Rubin’s Rules (Rubin, 1987), implemented using the mim command 
(version 1.1.8 (Carlin, Galati, and Royston, 2008)). For the adverse events analysis, multiple 
imputation was not used.  
Figure 1  
 
RESULTS 
We assessed 890 children (764 through community screening, 129 through clinical 
referral) for eligibility and 122 (73 community, 49 clinical) were randomized between June 
2005 and July 2008.  Participant characteristics by treatment group are shown in Table 1. 
Sixteen withdrew from the trial before week 16; 5 of the withdrawals, all on active 
medication, were due to adverse events (details in supplementary appendix). We followed 122 
participants until 16 weeks and all are included in the intention-to-treat analysis. Eighty-seven 
(47 active, 40 placebo) were rated as having good or excellent medication compliance and are 
included in a sensitivity analysis. The doses being taken (including none for those withdrawn) 
are shown in the supplementary appendix. 
Table 1  
Behavioural Outcome 
 Table 3 shows that participants receiving active medication experienced a significantly 
greater reduction in parent- and teacher-rated symptoms on the Conners ADHD index. 
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Significant group differences were also seen for the parent and teacher Conners hyperactivity 
scale and the ABC hyperactivity scale. On the CGI-I, 24 of 61 (40%) participants receiving 
methylphenidate were rated as improved or better, compared to 4 of 57 (7.1%) of those on 
placebo, giving a number needed to treat (NNT) of 3. Sensitivity analysis including compliers 
only reported similar effect sizes to those seen in the intention to treat analysis (Table 2). 
Table 2  
Moderators of Response 
 None of the candidate moderators (IQ, autistic symptoms, parent- and teacher-rated 
ADHD severity) had an effect on parent- or teacher-rated Conners ADHD index at 16 weeks 
with p values ranging from 017 to .94. 
Table 3  
Adverse Effects 
 Children taking methylphenidate were more likely to have parent reports of sleep 
difficulties and poor appetite but the other parent-reported adverse events showed non-
significant group differences (Table 3). There were no group differences in mean change in 
pulse or blood pressure. However, weight change from baseline differed significantly between 
groups (Table 4). The target adverse effects score decreased for both groups between baseline 
and week 16. There was a marginally-significant trend for the active treatment group to 
decrease less over the course of treatment. The other adverse effects score also showed a 
reduction for both groups between baseline and week 16 with no group difference.  
 Comparing the means and standard errors (SEs) of all 16 withdrawals (from both arms) 
to the non-withdrawals revealed a mean (SE) IQ of 51.8 (2.6) vs. 53.7 (1.0) and mean (SE) 
SCQ scores of 15.1 (1.9) vs. 17.4 (0.8), respectively. A similar comparison amongst only 
those receiving active medication and comparing the 5 withdrawn because of likely/definite 
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adverse effects vs. the 51 remaining on active medication revealed a mean (SE) IQ of 47.2 
(4.7) vs. 54.1 (1.3) and SCQ scores of 18.4 (2.0) vs. 16.9 (1.1). 
Table 4 
 
CONCLUSIONS 
Methylphenidate is effective in reducing ADHD symptoms in children with 
intellectual disability; the results reveal moderate effect sizes of 0.39-0.52 for the primary 
outcome of parent and teacher ADHD index. Some researchers have argued that the 
hyperactivity scale of the ABC is a more suitable measure for children with ID and it is 
interesting to note the parent (but not the teacher) effect size is larger and more consistent 
than seen for the Conners scales. However, the Conners scales provide comparability both to 
other studies of children with ID and also to the wider literature on children of average ability. 
A responder/non-responder classification using the CGI shows a highly significant (p<.001) 
group difference but this is partly driven by the relative absence of a placebo effect, with only 
7% of those receiving placebo being responders. Other studies with a similar participant 
group have used a crossover design and placebo effects are largely unreported. 
 The present findings, including the effect sizes, are consistent with the previous 
literature. Aman’s summary of the aggregated crossover trials of methylphenidate versus 
placebo, which reported a mean effect size of 0.57 for the four teacher-reported hyperactivity 
measures and 0.39 for the parallel parent scales (Aman, et al., 2003). However, because of the 
design differences in the present study, it cannot be inferred that the finding of similar effect 
sizes indicate that the use of individually titrated optimal three times daily dosing does not 
achieve better results than group-standardized, twice-daily dosing. Furthermore the trial end-
point is significantly longer than that reported in previous trials. 
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 This is the first trial to formally examine the role of treatment moderators such as IQ, 
autistic symptoms and ADHD severity. In the aggregate studies, Aman suggested that lower 
IQ/mental age might predict poorer treatment response. In our larger sample, we found no 
support for this. The studies aggregated by Aman included individuals with IQs up to 90 and 
it may be that the suggestive difference reported is due to greater response in those with 
IQ>70, rather than a difference among those in the ID range. The present finding of no 
subgroup difference according to autistic symptoms is in line with the findings in children 
with an ASD and high levels of hyperactivity, in which effect sizes for methylphenidate 
ranged from 0.20 to 0.54 (Research Units on Pediatric Psychopharmacology (Autism 
Network), 2005). Taken together, these two studies support the use of stimulant medication in 
children with combined ADHD and ASD symptoms. The current criteria do not allow the 
diagnoses of ADHD/hyperkinetic disorder when an ASD has been diagnosed. This is likely to 
change in the revisions of the DSM and ICD criteria and the current findings support this 
alteration in showing that children who likely meet both sets of criteria can benefit from 
stimulant treatment. We found that ADHD symptom severity did not predict response 
amongst those receiving a diagnosis of hyperkinetic disorder. In the present trial, 60% of the 
participants were not clinically recognized or treated for their ADHD symptoms; these 
findings suggest that clinicians should be more aware of the increased rate of ADHD among 
children with ID and the potential benefits of stimulant treatment, even amongst those with 
milder symptoms. 
The rate of withdrawals, 13%, is similar to that reported in other studies of similar 
populations (Aman, Kern, McGhee, and Arnold, 1993;  Research Units on Pediatric 
Psychopharmacology (Autism Network), 2005); furthermore, it should be noted that only 4% 
were withdrawn due to adverse effects. Nevertheless, treatment with methylphenidate 
produced significantly more adverse effects than seen with placebo. The adverse effects 
 - 15 - 
profile was typical of methylphenidate, with sleep and appetite difficulties along with failure 
to gain weight. It is notable that these difficulties were seen even when participants were 
prescribed an optimally selected dose, in which acceptability of any adverse effects were 
considered. This highlights the need to regularly review adverse effects even when an initial 
dose has been carefully selected. However, it is interesting to note that the target adverse 
effects score decreased for both groups, indicating overall improvement, between baseline and 
week 16. Explanations for this include the fact that many adverse effects can also be 
indicators of comorbidity or alternatively that initial high scores show regression to the mean.  
 The current study has a number of strengths. The sample size is more than three times 
that of the next largest randomized double-blind study of methylphenidate in this population 
(Aman, et al., 1993). The larger sample size increases the precision of the effect size estimates 
and also allows the moderating effects of IQ, autistic symptoms and ADHD severity to be 
tested. The length of follow-up (16 weeks) is substantially longer than any other trial and 
therefore provides the first data on medium-term effects of medication. The study employed 
an intention to treat analysis and all but one participant was followed up until 16 weeks. All 
diagnoses of ADHD/hyperkinetic disorder were carefully considered using a research clinical 
instrument, the CAPA, as well as teacher Conners and direct behavioural observation; the 
combined information was reviewed in the context of participants’ IQ results by at least one 
experienced clinician. The recruitment strategy included both clinically identified cases and 
also children in whom ADHD had not been previously recognized. Therefore the present 
findings are generalizable to the wider population of children with ADHD and ID. The dose 
optimization strategy employed in the current study was close to current clinical practice.  
A potential limitation of the present study is the number of participants (33, 27%) with 
poor medication compliance. However, this proportion broadly reflects the experience in UK 
health care and should be considered a reflection of the representative nature of the sample.  It 
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is interesting to note that the effect sizes from the sensitivity analysis that included only good 
compliers were similar to those from the full intention to treat analysis. Although the current 
trial is much larger than any previous study, the sample size is powered for the main effect of 
medication on ADHD symptoms and not for the moderating influences that were tested. 
Although the failure to identify any significant interaction must therefore be viewed with 
caution, it should also be noted that none of these effects approached significance.  This 
suggests that any such moderating influence is likely to be subtle. 
The study has three main findings. First, methylphenidate is effective in about 40% of 
children with hyperkinetic disorder and ID. Second, the adverse effects experienced by this 
population are similar to those seen in typically developing children with ADHD and can be 
identified with careful but routine monitoring of medication. The current study cannot 
exclude the presence of rare, atypical adverse events, but these apply to any population of 
children treated with medication. Nevertheless, because children with ID often have 
complicating medical problems and are less likely to be able to communicate subjectively 
experienced adverse events, particular care should be exercised in prescribing and monitoring 
stimulant medication. Finally, we found no evidence to support moderating effects of IQ, 
autistic symptoms or ADHD severity. Therefore, stimulants should be considered in children 
with hyperkinetic disorder and ID regardless of their profile with respect to these 
characteristics. 
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What is known 
 ADHD and hyperkinetic disorder (HD)  are increased about 8-fold in children 
with intellectual disability (ID)  but often goes unrecognized 
 Methylphenidate is the first line medication for children with ADHD/HD but  
the large, two-arm trials have excluded children with ID 
What is new 
 Treatment with methylphenidate was superior to placebo in reducing ADHD 
symptoms and producing clinical improvement 
 Assessment of common adverse effects of insomnia, poor appetite and weight 
loss were associated with methylphenidate treatment but overall safety was 
good 
What is clinically relevant 
 ADHD/HD is important to identify and treat in children with ADHD/HD 
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Table 1 
Participant Baseline characteristics 
 Treatment Group 
Characteristic 
  
Overall  
(N=122) 
Placebo 
(N=61) 
Methylphenidate 
(N=61) 
Type of referral  (n, %clinical referral) 
a 
73 (60) 36 (59) 37 (61) 
Severity of intellectual disability (N, % IQ<50) 39 (32) 20 (33) 19 (31) 
IQ (mean, SD)
b 
53(10·1) 53 (10·5) 54(9·6) 
Age in months  (mean, SD)
c 
134 (28) 138 (28) 130 (29) 
Sex  (N, % male)
d 
85 (70) 40 (66) 45 (74) 
Type of school (N, % mainstream school) 
e 
33 (27) 17 (28) 16 (26) 
Teacher medication preference (N, % prefer 
active medication) (N=114) 
32 (27) 16 (27) 16 (27) 
Parent medication preference (N, % prefer 
active medication) 
f 
91 (75) 48 (79) 43 (70) 
Clinician medication preference (N, % prefer 
active medication) (N=117) 
80 (66) 39 (67) 41 (69) 
Parental education (n, % GCSE or lower 
qualification) (N=119)
g 
67(55) 30 (49) 37 (61) 
SCQ (Mean, SD) (N=118)
h 
17·1 (8·0) 17·3 (8·7) 16·9 (7·3) 
Parent Conners ADHD index (Mean, SD) 
(N=121) 
i 
27·6 (5·9) 27·8 (5·1) 27·4 (6·6) 
Teacher Conners ADHD index (Mean, SD)
 
(N=120) 
j 
20·6 (9·5) 19·7 (9·7) 21·5 (9·3) 
Parent Conners hyperactivity scale (Mean, SD) 12·0 (3·8) 12·1 (3·7) 12·0 (4·0) 
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(N=121)
k 
Teacher Conners hyperactivity scale (Mean, 
SD)
 
(N=120)
l 
9·9 (5·9) 9·6 (5·8) 10·1 (6·0) 
Parent ABC hyperactivity subscale (Mean, SD) 
(N=121)
m 
31·7 (9·2) 32·6 (9·7) 30·8 (8·7) 
Teacher ABC hyperactivity subscale (Mean, 
SD)
 
(N=121)
n 
21·2 (13·4) 20·5 (13·7) 21·9 (13·0) 
Parental stress index (Mean, SD)
 
(N=121)
o 
105·9 
(22·0) 
104·1 (20·1) 107·8 (23·8) 
Weight (Kg) mean (SD) (N=121) 41·15 
(17·5) 
40·99 (14·9) 41·31 (19·9) 
Blood pressure: Diastolic,  mean (SD) (N=113)  66·6 (8·9) 67·0 (9·1) 66·2 (8·7) 
Blood pressure: Systolic,  mean (SD) (N=113) 103·1 
(12·3) 
103·2 (12·3) 103·4 (12·4) 
 
a-g were included in the multiple imputations model.  
h-o were pro-rated where there was less than 10% items missing. If there were more than 10% 
items missing, the scale score was recorded as missing.  
h-o were included in the multiple imputations model after pro-rating.  
Week 16 outcome values of i-o were included in the multiple imputation model as were 
screening values of i and j.  
Treatment group and CGI-I score at week 16; and impact of childhood disability and 
Conners’ symptoms score at baseline and week 16 were also included in the multiple 
imputation model.  
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Table 2 
Effect of Treatment on Primary and Secondary ADHD Measures, Intention to Treat 
 Methylphenidate 
Mean (se) 
Placebo 
Mean (se) 
Group difference 
in the mean 
difference 
between the time-
points (95% CI)* 
p-
value 
Adjusted Effect 
size–unadjusted SD 
(95% CI)  Baseline 16 Weeks Baseline 16 Weeks 
Intention to treat 
Parent ADHDI Index 
 
27·4  
(0·8) 
19·1 
(1·4) 
27·8  
(0·7) 
22·4 
(1·1) 
-3·8 
(-6· 7, -0·9) 
0·011 0·39 
(0·09, 0·70) 
Teacher ADHD Index 21·5  
(1·2) 
14·5 
(1·2) 
20·0  
(1·3) 
18·6 
(1·3) 
-5·1 
(-7· 9,-2·2) 
0·001 0·52 
(0·23, 0·82) 
Parent Hyperactivity Scale 12·0  
(0·5) 
7·7 
(0·7) 
12·1 
(0·5) 
9·2 
(0·7) 
-1·8 
(-3·4,-0·2) 
0·03 0·33 
(0·03, 0·63) 
Teacher Hyperactivity Scale 10·1  
(0·8) 
6·4 
(0·7) 
9·8 
(0·8) 
9·0 
(0·8) 
-3·2 
(-4·9, -1·5) 
<0·001 0·54 
(0·25, 0·82) 
Parent ABC Hyperactivity 
Scale 
31·0  
(1·1) 
20·6 
(1·6) 
32·6  
(1·2) 
28·7 
(1·6) 
-6·8 
(-10·2,-3·5) 
<0·001 0·56 
(0·29, 0·83) 
Teacher ABC Hyperactivity 
Scale 
21·8  
(1·7) 
13·2 
(1·5) 
20·5  
(1·8) 
18·1 
(1·7) 
-6·7 
(-10·0,-3·3) 
<0·001 0·54 
(0·26, 0·81) 
Compliers only  
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Parent ADHD Index 
 
27·9 
(0·9) 
18·2 
(1·6) 
27·4 
(0·8) 
21·6 
(1·4) 
-3·40 
(-6·89, -0·08) 
0·055 0·33 
(-0·01, 0·68) 
 
Teacher ADHD Index 22·4 
(1·3) 
13·8 
(1·3) 
20·2 
(1·6) 
18·0 
(1·8) 
-5·83 
(-9·32,-2·35) 
0·001 0·57 
(0·23, 0·91) 
Parent Hyperactivity Scale 12·2 
(0·6) 
7·1 
(0·8) 
11·9 
(0·6) 
8·9 
(0·8) 
-1·91 
(-3·76,-0·06) 
0·043 0·36 
(0·01, 0·72) 
Teacher Hyperactivity Scale 10·8 
(0·9) 
6·1 
(0·7) 
9·9 
(0·9) 
8·7 
(1·1) 
-3·51 
(-5·50, -1·52) 
0·001 0·58 
(0·25, 0·91) 
Parent ABC Hyperactivity 
Scale 
32·6 
(1·2) 
19·4 
(1·8) 
33·0 
(1·4) 
29·1 
(1·9) 
-8·77 
(-12·58,-4·95) 
<0·001 0·74 
(0·42, 1·06) 
Teacher ABC Hyperactivity 
Scale 
22·5 
(1·9) 
12·3 
(1·7) 
21·9 
(2·1) 
18·5 
(2·1) 
-6·94 
(-11·08,-2·80) 
0·001 0·56 
(0·22, 0·87) 
 
* Group differences are adjusted for the randomisation factors, age, sex, baseline SCQ score, and the screening and baseline values of the 
outcome 
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Table 3 
Individual adverse events at 16 weeks 
 
 Number  (%) of participants 
reporting significant increases 
p-value 
 Methylphenidate Placebo  
Trouble getting to sleep 13 (21) 2 (3) <0·01 
Poor appetite 9 (15) 1 (2) 0·02 
Looks sad/miserable 2 (3) 3 (5) 1 
Crying 0 1 (2) 1 
Looks anxious 2 (3) 1 (2) 0·99 
Meaningless repetitive behavior 4 (7) 4 (7) 1 
Talks less with other children 3 (5) 1 (2) 0·66 
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Table 4 
Mean changes indicative of possible adverse events 
 
 Methylphenidate 
Mean (sd) 
Placebo 
Mean (sd) 
Group difference in 
the mean difference 
between the time-
points (95% CI)* 
p-value 
 Baseline Week 16 Baseline Week 16 
Weight 
1 
41·3  
(19·9) 
39·6 
(17·3) 
41·0 
(14·9) 
43·8 
(16·8) 
-2·70 
(-3·72,-1·67) 
<0·001 
Pulse 
2 
81·5 
(9·7) 
84·5 
(10·0) 
77·7 
(11·1) 
78·9 
(10·8) 
1·43 
(-3·38, 6·24) 
0·556 
Systolic BP 
3 
103·0 
(12·4) 
104·2 
(11·5) 
103·2 
(12·3) 
102·1 
(12·1) 
3·11 
(-1·81, 8·02) 
0·213 
Diastolic BP 
4 
66·2 
(8·7) 
67·6 
(9·8) 
67·0 
(9·1) 
64·4 
(9·4 ) 
3·29 
(-1·00, 7·58) 
0·131 
Target adverse 
effects score 
5 
6·8 
(5·3) 
5·4 
(4·5) 
8·3 
(4·9) 
5·1 
(4·3) 
1·55 
(-0·02, 3·12) 
0·053 
Other adverse 
effects score 
6 
10·1 
(6·8) 
6·5 
(5·3) 
11·2 
(4·7) 
7·9 
(4·4) 
-0·52 
(-2·32, 1·27) 
0·566 
 
* Group differences for the continuous outcomes are adjusted for the randomisation factors 
Group difference for the two adverse effects score are adjusted for gender, age and baseline 
SCQ 
Missing data as follows: 
1 Active group 2 at week 16; placebo group 1 at baseline, 4 at week 16 
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2 Active 4 at baseline, 7 at week 16; placebo 6 at baseline, 5 at week 16 
3 Active 6 at baseline, 4 at week 16; placebo 3 at baseline, 6 at week 16 
4 Active 6 at baseline, 4 at week 16; placebo 3 at baseline, 6 at week 16 
5 Active group 1 at baseline, 2 at week 16; placebo 1 at week 16 
6 Active 1 at baseline, 1 at week 16; placebo 2 at baseline, 1 at week 16 
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Figure 1 
Diagram of participant selection and enrolment to the trial 
 
 
 
 
  
Excluded from the Trial pre Interview (n=519; 58%) 
  Primary Eligibility Reason (n=227; 26%) 
    No diagnosis of hyperkinetic disorder (HD) (n=5) 
    IQ not between 30 and 69 at randomization (n=7) 
    Not aged between 7 and 15 at randomization (n=81) 
    Other primary eligibility reason (n=134) 
  Primary Consent Reason (n=292; 33%) 
    Parent declined (n=208) 
    Local clinician declined (n=1) 
    Repeated appointments missed (n=1) 
    Child declined (n=0) 
    Other (n=82) 
     
Assessed for Eligibility 
(n=890) 
Excluded from Trial at Interview (n=249;   28%) 
  Primary Eligibility Reason (n=187; 21%) 
     No diagnosis of hyperkinetic disorder (HD) (n=49) 
     IQ not between 30 and 69 at randomization (n=106) 
     Not aged between 7-15 years at randomization (n=2) 
    Other primary eligibility reason (n=30) 
  Primary Consent Reason (n=62; 7%) 
     Parent declined (n=39) 
     Local clinician declined (n=1) 
     Repeated appointments missed (n=12) 
     Child declined (n=2) 
     Other (n=8) 
     
       
Randomized 
(n=122) 
Allocated to placebo (n=61) 
Received allocated intervention (n=60) 
Allocated to methylphenidate (n=61) 
Received allocated intervention (n=58) 
 
Lost to follow-up (n=1) 
Reasons: Uncontactable (n=1) 
 
Discontinued intervention (n=6) 
Reasons: 
  Poor adherence (n=3) 
  Consent withdrawn (n=2) 
  Unable to attend appointments (n=1) 
 
Lost to follow-up (n=0) 
 
Discontinued intervention (n=10) 
Reasons: 
  Adverse events (n=5) 
  Consent withdrawn (n=3) 
  Delay in optimal dose (n=1) 
  Eligibility not met (n=1) 
Analyzed (n=61) 
Excluded from analysis (n=0) 
Analyzed (n=61) 
Excluded from analysis (n=0) 
 - 31 - 
SUPPLEMENTARY APPENDIX 
 
Role of the Funding Source:  
Study design, data collection, analysis and writing were fully independent of the 
funding body. 
Screening for eligible participants 
The purpose of screening with the parent and teacher short forms of the Conners rating 
scales was to identify children at risk for hyperkinetic disorder and intellectual disability. 
Previous research and clinical practice suggested this group of children are under-identified. 
Initially we set the age-related threshold for both parent and teacher ratings on either the 
ADHD index or hyperactivity scale at 90%. This was modified  during the recruitment phase 
(by substantive amendment) to 85% for teacher ratings based on experience during the trial 
that a proportion of children meeting clinical research criteria for hyperkinetic disorder, 
described below,  were falling under the 90% threshold on teacher ratings.  
Psychiatric diagnosis 
Hyperkinetic disorder was assessed by parental interview, undertaken by medical 
doctors in psychiatry and paediatrics, postgraduate research and clinical psychologists using 
the Child and Adolescent Psychiatric Assessment (CAPA; Angold, et al., 1995). The CAPA 
elicits behavioural accounts of hyperkinetic symptoms that were judged for their 
developmental appropriateness.  In addition, psychologists recorded the child’s behaviour 
during individual assessments of cognition and a free play/structured activities task designed 
to assess activity, attention and impulsivity with a descriptive commentary.  Where teacher 
Conners ratings were at odds with parental accounts and researcher observations, a school 
observation was completed using a recording sheet to describe overactivity, inattention and 
impulsivity. A vignette using all sources of information described above was independently 
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rated for ICD-10 criteria by at least one senior investigator (ES), with a second opinion (ET, 
GB, SB, OC) in borderline cases.  Mood and anxiety disorders were screened to ensure they 
did not account for the current symptom presentation. Autistic symptoms were quantified 
using the Social Communication Questionnaire (Rutteret al., 2003) but the exclusion was not 
applied. 
Intellectual assessment 
IQ was measured using the Wechsler Intelligence Scales for Children-IV (WISC-IV-
UK (Wechsler, Rust, & Golombok, 2004), the Wechsler Preschool and Primary School 
Intelligence Scales (WPPSI-III; Wechsler, 2004)) or the Mullen Scale of Early Learning 
(Mullen, 1997), according to the child’s age and estimated ability.  Ratio IQs were employed 
when cognitive assessments were used out of age range (to avoid floor effects in participants 
of low ability).  
Additional medical investigations 
Children with a personal history of structural cardiac disease were cleared by a 
paediatric cardiologist; those with a history of early (<40 years) sudden death in a first degree 
family member had an electrocardiogram prior to enrolment.   
Optimal dose titration 
Prescribing was rounded to the nearest 5 mgs using a standardized table to indicate the 
doses and tablet strength according to the participant’s weight.  The total daily dose was 
divided so that 40% was given in the morning and at lunchtime and 20% after school.  
Variation in the timing of the after school dose was permitted according to personal needs and 
possible adverse effects. Participants received each dose, in order of low, medium, high, for at 
least one week during which they were attending school and physically well. Assessments 
during titration, used parent and teacher adverse effects ratings, reviewed personally by the 
medical doctor, to   determine tolerability and safety of proceeding to the next dose. Although 
 - 33 - 
parent and teacher Conners rating were obtained for optimal dose selection, these were not 
formally reviewed during titration. For optimal dose selection (undertaken blind to trial arm), 
each dose was first rated according to the acceptability of any possible adverse events. 
Amongst the doses judged acceptable, the one showing greatest behavioural improvement 
was selected as optimal. When no clinical difference between two doses could be identified, 
the higher dose was selected. Where senior investigators selected different doses, a consensus 
meeting was arranged and bringing in a third senior investigator if required. 
Adverse effects 
Parents and teachers completed a standard questionnaire on adverse effects (Hill & 
Taylor, 2001) augmented with additional symptoms seen in children with developmental 
disorders. Symptom ratings were on a 5-point scale (not at all, a few occasions only, about 
half the time, most of the time, all the time); these were compared with baseline ratings on the 
same scale. Clinical ratings of medication acceptability involved telephone interviews with 
parents at low dose and face-to-face parental interviews and physical examination at medium 
and high dose titration and at 8, 12 and 16 weeks post-randomization. During titration, an 
algorithm of number and severity of possible adverse events guided decisions about 
increasing dose.   
For the analysis of adverse effects at 16 weeks, only the parent reports were used. This 
was decided upon a priori based on the observation during the titration phase that many 
teacher reports were inaccurate in their observation when followed up with a personal 
telephone call (e.g., describing stereotypies as tics).  
Withdrawals due to adverse effects 
There were 5 withdrawals due to adverse effects, all in the methylphenidate arm. 
These included, by participant: a combination of irritability, poor appetite and aggression; 
nausea and diarrhoea; blurred vision; urticaria; and irritability combined with social 
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withdrawal. An additional 11 children withdrew, 5 (3 active, 2 placebo) withdrawing consent 
after randomization, 3 (all placebo) due to poor medication adherence, 1 each because: 
eligibility criteria were not met on review (active arm); delay in reaching optimal dose 
(active); and failure to attend appointments (placebo). 
Compliance 
 Compliance was rated at each visit by clinicians by asking parents how many doses 
the child had missed in the last week (the period under review for symptomatic 
improvement). In addition, the questionnaires sent to schools asked teachers to indicate 
whether the child had received all, some or none of the school day doses. This information 
was used to generate a rating of: all; most; some; few/no doses, completed at each assessment 
visit. Those for whom the rating at 16 weeks was most or all doses were considered 
compliers. Doses taken at 16 weeks are as follows: 
Dose taken Methylphenidate N (%) Placebo N (%) 
Low 8 (13·1%) 6 (9·8%) 
Medium 14 (23·0%) 17 (27·9%) 
High 28 (45·9%) 26 (42·6%) 
None 11 (18·0%) 12 (18·6%) 
where none includes whose optimal dose was selected as ‘none’ and those not taking 
medication regularly. 
